Quality Assessment of Published Articles in Iranian Journals Related to Economic Evaluation in Health Care Programs Based on Drummond’s Checklist: A Narrative Review

Aziz Rezapour1,2,3, PhD; Abdosaleh Jafari2, MS; Kosha Mirmasoudi4, BS; Hamid Talebianpour4, BS

1Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran;
2Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran;
3Center of Excellence in Health Management and Economics, Iran University of Medical Sciences, Tehran, Iran;
4Student Research Committee, Department of Health Care Management, School of Management and Medical Information, Shiraz University of Medical Science, Shiraz, Iran

Correspondence:
Abdosaleh Jafari, MS; Department of Health Economics, School of Health Management and Information Sciences, Rashid Yasemi Street, Vanak Square, Valiasr Street, Postal Code: 19967-13883, Tehran, Iran
Tel: +98 21 88794301
Fax: +98 21 88883334
Email: abdosaleh.jafari@gmail.com
Received: 29 February 2016
Revised: 04 May 2016
Accepted: 12 June 2016

Abstract
Health economic evaluation research plays an important role in selecting cost-effective interventions. The purpose of this study was to assess the quality of published articles in Iranian journals related to economic evaluation in health care programs based on Drummond’s checklist in terms of numbers, features, and quality. In the present review study, published articles (Persian and English) in Iranian journals related to economic evaluation in health care programs were searched using electronic databases. In addition, the methodological quality of articles’ structure was analyzed by Drummond’s standard checklist. Based on the inclusion criteria, the search of databases resulted in 27 articles that fully covered economic evaluation in health care programs. A review of articles in accordance with Drummond’s criteria showed that the majority of studies had flaws. The most common methodological weakness in the articles was in terms of cost calculation and valuation. Considering such methodological faults in these studies, it is anticipated that these studies would not provide an appropriate feedback to policy makers to allocate health care resources correctly and select suitable cost-effective interventions. Therefore, researchers are required to comply with the standard guidelines in order to better execute and report on economic evaluation studies.

Keywords ● Iranian journals ● Cost-benefit analysis ● Checklist ● Economics ● Medical ● Review

Introduction
Economic evaluation compares the costs and consequences of two or more health interventions to achieve the best choice. Its overall objective is to maximize the benefits due to resource constraints.1 The cost-effectiveness analysis can be applied as a guide to rank priority setting and make a rational decision when introducing drugs or new health technologies.2

In recent years, there has been an upsurge of using economic evaluation in health care resource allocation and decision-making across the developed and Asian countries. Countries such as Australia, England, Wales, and Sweden have formally adopted the use of economic evaluation in pricing drugs, development of
clinical practice guidelines and communication with health professionals. In Asian countries, although countries such as South Korea, China, Thailand and Taiwan use the methods of economic evaluation, among them, only South Korea has adopted economic evaluation as a formal tool for medical decision making.3

Iran is a country with a middle-income and the gross national income (GN) per capita in 2013 was US $15,600. Approximately 6.7% of the gross domestic production (GDP) is spent on health care.4 Over the past few decades, health care expenditure in Iran has risen for many reasons, including aging population, increased prevalence of noncontiguous and chronic diseases, increased prescription and taking drugs, and improved usage of new medical technologies.5,6 In recent years, studies published in Iran on economic evaluation of health care have increased. Nevertheless, decisions regarding medical technology, pricing of medicines, and reimbursement rules are taken without economic evaluation considerations. It seems that many decisions are based on experts’ opinion and experience.7

The present study examines the quality of the structure of all articles published in Iranian journals (Persian and English) dealing with the economic evaluation of health care during 1990 and 2014. We aimed at assessing the quality of published articles related to economic evaluation in health care programs based on Drummond’s checklist. The results of this research would assist researchers and decision-makers of the health system to properly design, implement, and present the results of economic evaluation studies.

Articles that had carried out full economic evaluation, including cost-effectiveness analysis, cost-utility analysis, and cost-benefit analysis were included. In this review, the methodological quality of the structure of articles was analyzed by Drummond’s standard checklist (table 1). Drummond’s checklist is used to assess the methodological quality of full economic evaluations with limited use of decision-analytic modeling (such as Markov modeling). To conduct the critical assessment of the methodological quality of economic modeling, Phillips checklist can also be used.8 Given that only one article conducted Markov model in the present study, we therefore, used Drummond’s checklist.1 All items in the checklist were scored according to positive, negative, or unclear.

Based on the inclusion criteria, we reviewed 27 articles that fully covered economic evaluation.9–35 The results showed that, of all the 27 studies, 12 (45%) were published in Persian. The number of studies in English related to health economic evaluation research has increased remarkably from 2011 to 2013 and the number of Persian articles reached a peak in 2013 (figure 1). In tables 2 and 3, the quality assessment of studies written in both English and Persian are reported. The results showed that 23 out of 27 studies (85%) in the fifth Drummond’s criteria, 22 studies (81%) in the sixth criteria, 21 studies (77%) in the tenth criteria, 19 studies (70%) in the fourth, and 18 studies (66%) in the seventh criteria had flaws. In table 4, the number of flaws in articles based on Drummond’s criteria is listed. Overall, the results indicated that in 6 criteria (second, third, fifth and eighth to tenth) the number of flaws in Persian articles were more than the English articles. In addition, the

| Table 1: Drummond’s criteria for the assessment of economic evaluation studies |
|---|
| Row | Criteria |
|---|
| 1 | Was a well-defined question posed? |
| 2 | Was a comprehensive description of the competing alternatives offered? |
| 3 | Was the evidence of the effectiveness of the program offered? |
| 4 | Were all important and relevant costs and consequences identified? |
| 5 | Were all important and relevant costs and consequences measured accurately? |
| 6 | Were all important and relevant costs and consequences have been properly valued? |
| 7 | Were the costs and consequences adjusted for different times? |
| 8 | Was an incremental analysis of costs and consequences of competing alternatives done? |
| 9 | Was the effect of uncertainty (sensitivity analysis) investigated in estimating the costs and consequences? |
| 10 | Were the presentation and analysis of all issues related to users of the results included? |

Figure 1: The number of full economic evaluations published in English and Persian per year in the Iranian journals. From 2011 to 2013, the number of English studies has risen considerably and in 2013 the number of Persian articles reached an apex.
Table 2: Assessment of methodological quality of English articles based on Drummond's checklist

| Row | Study                  | 1- Was a well-defined question posed? | 2- Was a comprehensive description of the competing alternatives offered? | 3- Was the evidence of the effectiveness of the program offered? | 4- Were all important and relevant costs and consequences identified? | 5- Were all important and relevant costs and consequences measured accurately? | 6- Were all important and relevant costs and consequences have been properly valued? | 7- Were the costs and consequences adjusted for different times? | 8- Was an incremental analysis of costs and consequences of competing alternatives done? | 9- Was the effect of uncertainty (sensitivity analysis) investigated in estimating the costs and consequences? | 10- Were the presentation and analysis of all issues related to users of the results included? |
|-----|------------------------|--------------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
| 1   | Sari[21]               | N/A                                  | +                                                                         | +                                                              | N/A                                                             | N/A                                                             | +                                                                              | +                                                               | +                                                               | N/A                                                             |
| 2   | Nikfar[28]             | +                                    | +                                                                         | +                                                              | +                                                               | +                                                               | +                                                               | +                                                               | +                                                               | N/A                                                             |
| 3   | Mehrzayy[4]            | +                                    | +                                                                         | +                                                              | -                                                               | +                                                               | -                                                               | +                                                               | +                                                               | N/A                                                             |
| 4   | Hatam[19]              | +                                    | +                                                                         | +                                                              | -                                                               | N/A                                                             | N/A                                                             | +                                                               | +                                                               | N/A                                                             |
| 5   | Keshtkaran[22]         | N/A                                  | +                                                                         | +                                                              | N/A                                                             | N/A                                                             | +                                                               | +                                                               | N/A                                                             |
| 6   | Soleymanii[14]         | +                                    | +                                                                         | +                                                              | -                                                               | N/A                                                             | N/A                                                             | +                                                               | N/A                                                             |
| 7   | Gharibnaseri[17]       | +                                    | +                                                                         | +                                                              | -                                                               | -                                                               | -                                                               | +                                                               | N/A                                                             |
| 8   | Rahbar[29]             | N/A                                  | +                                                                         | +                                                              | N/A                                                             | N/A                                                             | -                                                               | -                                                               | -                                                               | N/A                                                             |
| 9   | Aghili[10]             | +                                    | +                                                                         | -                                                              | N/A                                                             | -                                                               | -                                                               | -                                                               | N/A                                                             |
| 10  | Shamshir[21]           | +                                    | +                                                                         | +                                                              | N/A                                                             | N/A                                                             | +                                                               | +                                                               | N/A                                                             |
| 11  | Naghipour[29]          | N/A                                  | +                                                                         | +                                                              | N/A                                                             | N/A                                                             | -                                                               | -                                                               | -                                                               | N/A                                                             |
| 12  | Allameh[11]            | N/A                                  | +                                                                         | +                                                              | N/A                                                             | N/A                                                             | -                                                               | -                                                               | -                                                               | N/A                                                             |
| 13  | Divsalar[13]           | +                                    | +                                                                         | +                                                              | N/A                                                             | -                                                               | +                                                               | N/A                                                             | N/A                                                             |
| 14  | Yaghoub[25]            | N/A                                  | +                                                                         | +                                                              | N/A                                                             | N/A                                                             | -                                                               | +                                                               | -                                                               | +                                                               |
| 15  | Shahari[28]            | N/A                                  | +                                                                         | N/A                                                             | N/A                                                             | N/A                                                             | -                                                               | -                                                               | -                                                               | -                                                               |

Yes (+), No (-) and unclear (N/A)
### Table 3: Assessment of methodological quality of Persian articles based on Drummond’s checklist

| Row | Study | 1- Was a well-defined question posed? | 2- Was a comprehensive description of the competing alternatives offered? | 3- Was the evidence of the effectiveness of the program offered? | 4- Were all important and relevant costs and consequences identified? | 5- Were all important and relevant costs and consequences measured accurately? | 6- Were all important and relevant costs and consequences have been properly valued? | 7- Were the costs and consequences adjusted for different times? | 8- Was an incremental analysis of costs and consequences of competing alternatives done? | 9- Was the effect of uncertainty (sensitivity analysis) investigated in estimating the costs and consequences? | 10- Were the presentation and analysis of all issues related to users of the results included? |
|-----|-------|-------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| 1   | Ghaderi[16]| N/A      | +  | + | N/A | N/A | N/A | - | + | + | N/A |
| 2   | Keshtkaran[21]| + | + | + | + | N/A | N/A | + | + | + | N/A |
| 3   | Hatam[18]| + | + | + | - | N/A | N/A | + | + | + | N/A |
| 4   | Keshtkaran[21]| + | + | + | + | N/A | + | - | + | + | N/A |
| 5   | Asefzade[12]| N/A | - | - | N/A | N/A | N/A | - | - | - | - |
| 6   | Rasuli[30]| + | + | + | + | N/A | + | + | - | - | N/A |
| 7   | Foruzanfar[15]| + | + | + | + | + | - | - | + | + | N/A |
| 8   | Farazadegan[14]| N/A | + | + | N/A | N/A | N/A | - | - | N/A | N/A |
| 9   | Nakhaee[17]| + | + | + | - | - | - | - | - | N/A | N/A |
| 10  | Abolghasem[19]| N/A | + | + | N/A | N/A | N/A | - | + | - | N/A |
| 11  | Karimi[20]| N/A | + | + | N/A | N/A | N/A | + | - | - | N/A |
| 12  | Nakhaee[17]| + | + | + | - | N/A | N/A | - | - | N/A | N/A |

Yes (+), No (-) and unclear (N/A)
A review of health economic evaluation in Iranian journals

The economic characteristics of the studies are presented in Table 5. The results showed that among the 27 reviewed articles, 1 article performed the cost-benefit analysis, and the number of articles in connection with the cost-effectiveness and cost-utility analysis were 17 and 9, respectively. Among the studies that used cost-utility analysis (i.e. combined consequences such as quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs) to measure consequences), five studies used QALYs indicator, and four studies used DALYs indicator, in order to measure effectiveness. Most studies were carried out on health care services such as medical and pharmaceutical interventions, 8 studies evaluated screening programs, and only one study evaluated thalassemia prevention and care. Figure 2 shows the number of full economic evaluations published in the Iranian journals based on disease categories. “Endocrine, nutritional and metabolic diseases” were the most common diseases category covered by the economic evaluation studies.

Discussion

Economic evaluation evidence can play a prominent role in making decisions about

| Row | Drummond’s criteria                                                                 | English articles | Persian articles |
|-----|------------------------------------------------------------------------------------|------------------|------------------|
| 1   | Was a well-defined question posed?                                                 | 7 46             | 5 41             |
| 2   | Was a comprehensive description of the competing alternatives offered?            | 2 13             | 2 16             |
| 3   | Was the evidence of the effectiveness of the program offered?                     | 0 0              | 1 8              |
| 4   | Were all important and relevant costs and consequences identified?                 | 11 73            | 8 66             |
| 5   | Were all important and relevant costs and consequences measured accurately?       | 12 80            | 11 91            |
| 6   | Were all important and relevant costs and consequences have been properly valued? | 13 86            | 9 75             |
| 7   | Were the costs and consequences adjusted for different times?                     | 10 66            | 8 66             |
| 8   | Were an incremental analysis of costs and consequences of competing alternatives done? | 5 33             | 7 58             |
| 9   | Was the effect of uncertainty (sensitivity analysis) investigated in estimating the costs and consequences? | 7 46             | 6 50             |
| 10  | Were the presentation and analysis of all issues related to users of the results included? | 11 73            | 10 83            |

most common defects in Persian and English articles were in the fifth and sixth criteria, respectively. The most common methodological weakness of the articles was in the measurement and valuation of costs. Considering their perspective, only two articles performed full identification, measurement and valuation of costs. The economic characteristics of the studies are presented in Table 5. The results showed that among the 27 reviewed articles, 1 article performed the cost-benefit analysis, and the number of articles in connection with the cost-effectiveness and cost-utility analysis were 17 and 9, respectively. Among the studies that used cost-utility analysis (i.e. combined consequences such as quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs) to measure consequences), five studies used QALYs indicator, and four studies used DALYs indicator, in order to measure effectiveness. Most studies were carried out on health care services such as medical and pharmaceutical interventions, 8 studies evaluated screening programs, and only one study evaluated thalassemia prevention and care. Figure 2 shows the number of full economic evaluations published in the Iranian journals based on disease categories. “Endocrine, nutritional and metabolic diseases” were the most common diseases category covered by the economic evaluation studies.

Discussion

Economic evaluation evidence can play a prominent role in making decisions about
Table 5: Economic features of included studies

| Feature                                      | English journal | Persian journal | All             |
|----------------------------------------------|-----------------|-----------------|-----------------|
| **Type of economic evaluation**              |                 |                 |                 |
| CEA*                                         | 10 67 9 75 19 70 |                 |                 |
| CUA*                                         | 4 27 3 25 7 26  |                 |                 |
| CBA*                                         | 1 7 0 0 1 4     |                 |                 |
| **Study design**                             |                 |                 |                 |
| RCT *                                        | 2 13 0 0 2 7    |                 |                 |
| Observational                                | 7 47 8 67 15 56|                 |                 |
| Decision tree                                | 5 33 4 33 9 33  |                 |                 |
| Markov model                                 | 1 7 0 0 1 4     |                 |                 |
| **Perspective evaluated**                    |                 |                 |                 |
| Social                                       | 3 20 3 25 6 22  |                 |                 |
| Provider                                     | 4 27 3 25 7 26  |                 |                 |
| Patient                                      | 1 7 0 0 1 4     |                 |                 |
| Patient and provider (mixed)                 | 0 0 1 8 1 4     |                 |                 |
| Not stated                                    | 7 47 5 42 12 44 |                 |                 |
| **Type of sensitivity analysis**              |                 |                 |                 |
| One-way                                      | 6 40 5 42 11 41 |                 |                 |
| Multi-way                                    | 2 13 1 8 3 11   |                 |                 |
| Probabilistic                                | 0 0 0 0 0 0      |                 |                 |
| Not performed                                | 7 47 6 50 13 48  |                 |                 |
| **Time horizon**                             |                 |                 |                 |
| ≤1 year                                      | 7 47 9 75 16 59 |                 |                 |
| 1-10 years                                   | 2 13 1 8 3 11   |                 |                 |
| Over 10 years                                | 2 13 1 8 3 11   |                 |                 |
| Not specified                                | 4 27 1 8 5 19   |                 |                 |
| **Type of outcome**                          |                 |                 |                 |
| QALY/DALY*                                   | 6 40 3 25 9 33  |                 |                 |
| Intermediate (physiological, functional, etc.) | 10 67 10 83 20 74 |                 |                 |
| Money units                                  | 0 0 0 0 0 0      |                 |                 |
| **Discount rate**                            |                 |                 |                 |
| 3%                                           | 3 20 3 25 6 22  |                 |                 |
| 5%                                           | 0 0 1 8 1 4     |                 |                 |
| >5%                                          | 2 13 0 0 2 7     |                 |                 |
| Not stated                                    | 10 67 8 67 18 67|                 |                 |

**CEA**: Cost-effectiveness analysis; **CUA**: Cost-utility analysis; **CBA**: Cost-benefit analysis; **RCT**: Randomized controlled trial; **QALY**: Quality-adjusted life years; **DALY**: Disability-adjusted life years

resource allocation. Based on Drummond’s checklist, the present review examined the quality of the structure of all articles published in Iranian journals dealing with the economic evaluation of health care during 1990 and 2014. The results show that many published articles did not comply with the international standards for economic evaluation guidelines and had major methodological flaws. Such poor quality of economic evaluation studies is not unique to Iran. Studies from other developing and developed countries suffer from similar methodological faults.66-65 This is possibly due to a limited number of health economics specialists as well as the lack of knowledge by clinicians, policy makers, and managers in the field of economic evaluation.

Hosseinpour et al. showed that financial and administrative managers of hospitals in Iran do not have the appropriate level of knowledge in the field of health economics.66 Lack of specialized journals on health economics could also have exacerbated the situation. Neumann et al. reported that medical journals had a higher risk of reporting economic studies of poor quality.67 Determining the viewpoint of economic evaluation studies is important and has an effect on both costs and consequences.68 However, only 55% of the studies (15 out of 27) had a viewpoint. It shows that many authors are not aware of the importance of determining a viewpoint and its effect on costs and consequences. Among the studies that determined a viewpoint, many did not measure the costs associated with the viewpoint of the study. For example, in Mehrazmy and Hatam’s study, although the viewpoint of the study was the society, but indirect costs were not measured.18,19,24 Moreover, in studies with a viewpoint on service providers, the capital expenditures, equipment, and overhead costs had not been measured. Therefore, it can be argued that one of the major flaws in these studies is the lack of transparency in the recognition, measurement, and valuation of costs. Our results show that 44% of the studies did not calculate the incremental cost-effectiveness ratio. A number of studies reported the mean of cost-effectiveness ratio (total cost divided by total effectiveness). However, in turn, this could affect the main conclusions of a study and would lead to biased results. Another major weakness in economic evaluation studies in Iranian journals is the limited use of sensitivity analyses, to the extent that 48% of the studies (13 out of 27) had not conducted sensitivity analyses. Sensitivity analyses in economic evaluation studies are important. It measures the change rate of the incremental cost-effectiveness ratio in comparison with changes in parameters. It is used when dealing with the effect of uncertainty in results and in the generalizability of results.6 Another weakness of the studies is the authors’ lack of attention to the generalizability of results to the national level or to other settings, to the extent that only 25% of the studies had paid attention to this topic. Moreover, the results showed that cost-effectiveness analysis is the most common method for economic evaluation in published articles. A possible reason is that obtaining data on intermediate consequences (physiological consequences) is easier and less costly in comparison with the final consequences (QALYs or DALYs). Similarly, the results of...
A review of health economic evaluation in Iranian journals

Teerawattananon’s study showed that cost-effectiveness analysis was the most common type of economic evaluation in Thailand. Considering limited resources, it is expected that economic evaluation studies must be conducted on interventions, which have a significant effect on the health of the population. However, the results of this study showed that most economic evaluation studies were carried out on diseases that are of no concern to the Iranian health system. For example, more than 40% of the burden of the diseases in our country is due to injuries and mental illnesses. However, none of the studies covered the economic evaluation analysis of injuries and mental illnesses. Moreover, the findings of this study suggest that researchers paid more attention to cure rather than preventive health care. These findings are consistent with studies by Teerawattananon, Neumann, and Catalá-López.

There are a couple of limitations in the present study. We only reviewed studies published in the national journals of Iran. Articles published in international journals regarding the economic evaluation of health care were excluded from the study since they had a better quality compared with their Iranian equivalent. Another limitation of this review was that unpublished studies were not identified by our literature search. These were typically reports from the department of health technology assessment and health economics department of the ministry of health and medical education, medical schools, reports from health insurance organizations as well as pharmaceutical companies and academic thesis.

Conclusion

The results showed that the economic evaluation literature in Iran is still in its infancy and many of these studies suffer from common methodological faults. Furthermore, the majority of these studies did not cover the main health concern in Iran. Therefore, researchers are required to comply with the standard guidelines in order to better execute and report on economic evaluation studies. Recommended guidelines are Drummond’s checklist, consolidated health economic evaluation reporting standards (CHEERS checklist) and the grading system for the quality of cost-effectiveness studies (Chiou’s system).

Acknowledgement

We would like to thank all those who cooperated in collecting and analyzing the data.

Conflict of Interest: None declared.

References

1. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford university press; 2015. 464 p.
2. Eckard N, Janzon M, Levin LA. Use of cost-effectiveness data in priority setting decisions: experiences from the national guidelines for heart diseases in Sweden. Int J Health Policy Manag. 2014;3:323-32. doi: 10.15171/ijhpm.2014.105. PubMed PMID: 25396208; PubMed Central PMCID: PMC4226622.
3. YothasamutJ,TantivessS,Teerawattananon Y. Using economic evaluation in policy decision-making in Asian countries: mission impossible or mission probable? Value Health. 2009;12 Suppl 3:S26-30. doi: 10.1111/j.1524-4733.2009.00623.x. PubMed PMID: 20586976.
4. World Health Organization. Countries, Iran (Islamic Republic of) [Internet]. Geneva: WHO; c2014. Available from: http://www.who.int/countries/irn/en.
5. Davari M, Haycox A, Walley T. The Iranian health insurance system; past experiences, present challenges and future strategies. Iran J Public Health. 2012;41:1-9. PubMed PMID: 23193499; PubMed Central PMCID: PMC3494208.
6. Zakeri M, Olyaeemanesh A, Zanganeh M, Kazemian M, Rashidian A, Abouhalaj M, et al. The financing of the health system in the Islamic Republic of Iran: A National Health Account (NHA) approach. Med J Islam Repub Iran. 2015;29:243-50. PubMed PMID: 26793634; PubMed Central PMCID: PMC4715399.
7. Palesh M, Tishelman C, Fredrikson S, Jamshidi H, Tomson G, Emami A. “We noticed that suddenly the country has become full of MRI”. Policy makers’ views on diffusion and use of health technologies in Iran. Health Res Policy Syst. 2010;8:9-18. doi: 10.1186/1478-4505-8-9. PubMed PMID: 20370906; PubMed Central PMCID: PMC2907640.
8. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24:355-71. doi: 10.2165/00019053-200624040-00006. PubMed PMID: 16605282.
1. Hatami S. Evaluation and cost-effectiveness analysis of prevention program of major thalassemia in Sistan-Balouchestan and Fars provinces. Hakim Health Systems Research Journal. 2006;8:8-14. Persian.

2. Aghili R, Khamseh ME, Malek M, Yarahmadi S, Farshchi A. Structured self monitoring of blood glucose in Iranian people with type 2 diabetes: A cost consequence analysis. Daru. 2012;20:32-7. doi: 10.1186/2008-2231-20-32. PubMed PMID: 23351493; PubMed Central PMCID: PMC3555770.

3. Allameh Z, Davari M, Emami MH. Cost-effectiveness analysis of colorectal cancer screening methods in Iran. Arch Iran Med. 2011;14:110-4. doi: 011142/AIM.008. PubMed PMID: 21361717.

4. Asefzadeh S, Rezapour A, Amini S. Economic evaluation of students' screening program in the city of Komijan (Iran-2009). Journal of Qazvin University of Medical Sciences. 2012;16:81-6. Persian.

5. Divsalar K, Mahmoodi M, Nakhaee N. Economic appraisal of urine opiates screening test: a study in kerman, iran. Addict Health. 2011;3:79-84. PubMed PMID: 24494120; PubMed Central PMCID: PMC3905529.

6. Farajzadegan Z, Mirmoghftadeh P, Mehrabian F. Screening of asymptomatic bacteriuria: Urinalysis or Urine culture? Which one is more cost-effective? Journal of Isfahan Medical School. 2006;26:119-26. Persian.

7. Foruzanfar M, Majdzaede M, Jamali M. Cost-effectiveness of using Optometrists instead of trained instructors in amblyopia screening children. Journal of school of public health and institute of public health research. 2009;3:87-99. Persian.

8. Ghaderi H, Ameri H, Vafainsab M. Cost-effectiveness of home care and hospital care for stroke patients. Journal of health care management. 2013;4:7-15. Persian.

9. Gharibnaseri Z, Kebrabioezadeh A, Nikfar S, Zamani G, Abdollahi Asli A. Cost-effectiveness of adding-on new antiepileptic drugs to conventional regimens in controlling intractable seizures in children. Daru. 2012;20:17-22. doi: 10.1186/2008-2231-20-17. PubMed PMID: 23351726; PubMed Central PMCID: PMC3555750.

10. Hatam N, Shirvani S, Pourmohammadi K. Cost Utility of Neonatal Screening Program for Phenylketonuria in Shiraz University of Medical Sciences. Hakim Research Journal. 2013;16:329-36. Persian.

11. Hatam N, Shirvani S, Javanbakht M, Askarian M, Rastegar M. Cost-utility analysis of neonatal screening program, shiraz university of medical sciences, shiraz, iran, 2010. Iran J Pediatr. 2013;23:493-500. PubMed PMID: 24800006; PubMed Central PMCID: PMC4006495.

12. Karimi I, Zohour A, Vianchi A. Comparative study of cost-effectiveness of Dialysis and kidney transplant using DALY index in Shahid Haseheminejad Hospital. Journal of Health Administration. 2005;8:45-9. Persian.

13. Keshtkar A, Karimi R, Barouni M, Kavoosi Z, Jafari A. Cost-effectiveness Analysis of Type 2 Diabetes Screening: A case study in Shiraz, Iran. Journal of Health and Development. 2013;2:223-34. Persian.

14. Keshtkar A, Karimi R, Kavoosi Z, Jafari A, Barouni M. Economic Evaluation of Screening for Type 2 Diabetes: Case Study of Iran. Iranian Journal of Diabetes and Obesity. 2013;5:27-32.

15. Keshtkar A, Javanbakht M, Mirahmidzadeh A. Cost-effectiveness of Methadone Maintenance Treatment in Prevention of HIV Among IDUs. Payesh Journal. 2013;6:823-30. Persian.

16. Mehrazmay A, Alavian SM, Moradi-Lakeh M, Mokhtari Payam M, Hashemi-Meshkini A, Behnava B, et al. Cost-effectiveness analysis of adding low dose ribavirin to peginterferon alfa-2a for treatment of chronic hepatitis C infected thalassemia major patients in iran. Hepat Mon. 2013;13:e10236. doi: 10.5812/ hepatmon.10236. PubMed PMID: 24282420; PubMed Central PMCID: PMC3830516.

17. Naghipour B, Azarfarin R, Golzar S, Mirinazhad M, Bilehjani E, Negargar S. Cost-effectiveness of intraoperative transesophageal echocardiography in cardiac valve surgery. J Cardiovasc Thorac Res. 2011;3:79-81. doi: 10.5681/ jcvtr.2011.017. PubMed PMID: 24250959; PubMed Central PMCID: PMC3825334.

18. Nakhaee N, Sadeghi-Hassanabadi A. Cost-effectiveness analysis of Syphilis screening in Shiraz. Journal of Kerman University of Medical Sciences. 2000;7:65-72. Persian.

19. Nakhaee N, Divsalar K, Hasibi A. Cost-effectiveness of Urine opiates screening testing in Central Laboratory of Kerman in 2001. Hormozgan Medical Journal. 2006;10:291-5. Persian.

20. Nikfar S, Kebrabioezadeh A, Dinarvand R, Abdollahi M, Sahrain MA, Henry D, et al. Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis:
A review of health economic evaluation in Iranian journals

Decision analysis based on long-term clinical data and switchable treatments. Daru. 2013;21:50-63. doi: 10.1186/2008-2231-21-50. PubMed PMID: 23800250; PubMed Central PMCID: PMC3698128.

29. Rahbar M, Mardanpur K, Tahafzadeh R. Imprint cytology: a simple, cost effectiveness analysis for diagnosing Helicobacter pylori, in west of Iran. Med J Islam Repub Iran. 2012;26:12-6. PubMed PMID: 23483026; PubMed Central PMCID: PMC3587893.

30. Rasuli J, Holakui K, Foruzanfar M, Salari S, Bahonar M, Rashidian A. Cost-effectiveness of Vaccination of animals against brucellosis western Azarbayjan. Urmia Medical Journal. 2009;20:13-20. Persian.

31. Akbari Sari A, Ravaghi H, Mobinizadeh M, Sarvari S. The Cost-Utility Analysis of PET-Scan in Diagnosis and Treatment of Non-Small Cell Lung Carcinoma in Iran. Iran J Radiol. 2013;10:61-7. doi: 10.5812/iranjradiol.8559. PubMed PMID: 24046780; PubMed Central PMCID: PMC3767016.

32. Shajari A, Shajari H, Fallah-Zadeh MH. Cost Benefit of the Routine Urinalysis. Acta Med Iran. 2008;46:265-8.

33. Shamshiri AR, Yarahmadi S, Forouzanfar MH, Haghdoost AA, Hamzehloo G, Holakouie Naieni K. Evaluation of current guthrie TSH cut-off point in Iran congenital hypothyroidism screening program: a cost-effectiveness analysis. Arch Iran Med. 2012;15:136-41. doi: 012153/AIM.006. PubMed PMID: 22639300.

34. Soleymani F, Rashidian A, Dinavvarand R, Kebriaeezade A, Hosseini M, Abdollahi M. Assessing the effectiveness and cost-effectiveness of audit and feedback on physician’s prescribing indicators: study protocol of a randomized controlled trial with economic evaluation. Daru. 2012;20:88-94. doi: 10.1186/2008-2231-20-88. PubMed PMID: 23351564; PubMed Central PMCID: PMC3557192.

35. Yaghoubi M, Aghayan HR, Arjmand B, Emami-Razavi SH. Cost-effectiveness of homograft heart valve replacement surgery: an introductory study. Cell Tissue Bank. 2011;12:153-8. doi: 10.1007/s10561-009-9165-9. PubMed PMID: 19949875.

36. Al-Aqeel SA. State of health economic evaluation research in Saudi Arabia: a review. Clinicoecon Outcomes Res. 2012;4:177-84. doi: 10.2147/CEOR.S31087. PubMed PMID: 22826634; PubMed Central PMCID: PMC3401052.

37. Cooper N, Coyle D, Abrams K, Mugford M, Sutton A. Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997. J Health Serv Res Policy. 2005;10:245-50. doi: 10.1258/135581905774414187. PubMed PMID: 16259692.

38. Dalziek K, Segal L, Mortimer D. Review of Australian health economic evaluation - 245 interventions: what can we say about cost effectiveness? Cost Eff Resour Alloc. 2008;6:9-20. doi: 10.1186/1478-7547-6-9. PubMed PMID: 18489788; PubMed Central PMCID: PMC2413209.

39. Desai PR, Chandwani HS, Rascati KL. Assessing the quality of pharmacoeconomic studies in India: a systematic review. Pharmacoeconomics. 2012;30:749-62. doi: 10.2165/11590140-000000000-00000. PubMed PMID: 22720697.

40. Drummond MF, Iglesias CP, Cooper NJ. Systematic reviews and economic evaluations conducted for the National Institute for Health and Clinical Excellence in the United Kingdom: a game of two halves? Int J Technol Assess Health Care. 2008;24:146-50. doi: 10.1017/S026642340800116.

41. Garcia-Altes A. Twenty years of health care economic analysis in Spain: are we doing well? Health Econ. 2001;10:715-29. doi: 10.1002/hec.608. PubMed PMID: 11747053.

42. Gavaza P, Rascati K, Brown C, Lawson K, Mann T. The state of health economic and pharmacoeconomic evaluation research in Zimbabwe: A review. Curr Ther Res Clin Exp. 2008;69:268-85. doi: 10.1016/j.curtheres.2008.06.005. PubMed PMID: 24692805; PubMed Central PMCID: PMC3969967.

43. Gavaza P, Rascati KL, Oladapo AO, Khoza S. The state of health economic evaluation research in Nigeria: a systematic review. Pharmacoeconomics. 2010;28:539-53. doi: 10.2165/11536170-000000000-00000. PubMed PMID: 20550221.

44. Gavaza P, Rascati KL, Oladapo AO, Khoza S. The state of health economic evaluation research in South Africa: a systematic review. Pharmacoeconomics. 2012;30:925-40. doi: 10.2165/11589450-000000000-00000. PubMed PMID: 22809450.

45. Gavaza P, Shepherd M, Shcherbakova N, Khoza S. The state of health economics and pharmaceconomics research in Russia: a systematic review. J Pharm Health Serv Res. 2010;1:113-21. doi: 10.1111/j.1759-8893.2010.00023.x.

46. Hoque ME, Khan JA, Hossain SS,
Gazi R, Rashid HA, Koehlmoos TP, et al. A systematic review of economic evaluations of health and health-related interventions in Bangladesh. Cost Eff Resour Alloc. 2011;9:12-9. doi: 10.1186/1478-7547-9-12. PubMed PMID: 21771343; PubMed Central PMCID: PMC3158529.

47. Jiang S, Ma X, Desai P, Yang L, Rascati K. A Systematic Review on the Extent and Quality of Pharmacoeconomic Publications for China. Value Health Reg Issues. 2014;3:79-86. doi: http://dx.doi.org/10.1016/j.vhri.2014.02.010.

48. Lee KS, Brouwer WB, Lee SI, Koo HW. Introducing economic evaluation as a policy tool in Korea “Will decision makers get quality information?” A critical review of published Korean economic evaluations. Pharmaco economics. 2005;23:709-21. doi: 10.2165/00019053-200523070-00005. PubMed PMID: 15987722.

49. Machado M, Iskedjian M, Einarson TR. Quality assessment of published health economic analyses from South America. Ann Pharmacother. 2006;40:943-9. doi: 10.1345/aph.1G296. PubMed PMID: 16670369.

50. Mishra D, Nair SR. Systematic literature review to evaluate and characterize the health economics and outcomes research studies in India. Perspect Clin Res. 2015;6:20-33. doi: 10.4103/2229-3485.148802. PubMed PMID: 25657899; PubMed Central PMCID: PMC4314843.

51. Oliver A. Health economic evaluation in Japan: a case study of one aspect of health technology assessment. Health Policy. 2003;63:197-204. doi: 10.1016/S0168-8510(02)00066-0. PubMed PMID: 12543532.

52. Simoens S. Assessment of methodological quality of economic evaluations in belgian drug reimbursement applications. PLoS One. 2013;8:e85411. doi: 10.1371/journal.pone.0085411. PubMed PMID: 24386474; PubMed Central PMCID: PMC3875546.

53. Teerawattanon Y, Russell S, Mugford M. A systematic review of economic evaluation literature in Thailand: are the data good enough to be used by policy-makers? Pharmaco economics. 2007;25:467-79. doi: 10.2165/00019053-200725060-00003. PubMed PMID: 17523752.

54. Tran BX, Nong VM, Maher RM, Nguyen PK, Luu HN. A systematic review of scope and quality of health economic evaluation studies in Vietnam. PLoS One. 2014;9:e103825. doi: 10.1371/journal.pone.0103825. PubMed PMID: 25122180; PubMed Central PMCID: PMC4133226.

55. Walker D, Fox-Rushby JA. Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature. Health Econ. 2000;9:681-98. doi: 10.1002/1099-1050(200012)9:8%3C681::AID-HEC545%3E3.0.CO;2-X. PubMed PMID: 11137950.

56. Hoseinpour T, Hatam N, Jafari A, Najibi M, Dehghan H, Rezaee R. Executive and financial manager’s awareness of economic issues in private and public hospitals in Shiraz. Journal of Health Management and Informatics. 2014;1:66-70.

57. Neumann PJ, Rosen AB, Greenberg D, Olchanski NV, Pande R, Chapman RH, et al. Can we better prioritize resources for cost-utility research? Med Decis Making. 2005;25:429-36. doi: 10.1177/0272989X05276853. PubMed PMID: 16061895.

58. Hay JW, Smeeding J, Carroll NV, Drummond M, Garrison LP, Mansley EC, et al. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value Health. 2010;13:3-7. doi: 10.1111/j.1524-4733.2009.00663.x. PubMed PMID: 19874571.

59. Naghavi M, Abolhassani F, Pourmalek F, Lakeh M, Jafari N, Vaseghi S, et al. The burden of disease and injury in Iran 2003. Popul Health Metr. 2009;7:9-29. doi: 10.1186/1478-7954-7-9. PubMed PMID: 19527516; PubMed Central PMCID: PMC2711041.

60. Catala-Lopez F, Garcia-Altes A, Alvarez-Martin E, Genova-Maleras R, Morant-Ginestar C, Parada A. Burden of disease and economic evaluation of healthcare interventions: are we investigating what really matters? BMC Health Serv Res. 2011;11:75-84. doi: 10.1186/1472-6963-11-75. PubMed PMID: 21489236; PubMed Central PMCID: PMC3097252.